Table 1 The characteristics of the patients in derivation set and validation set
Variables | Derivation set | Validation set | p value |
|---|---|---|---|
N | 348 | 158 | |
Age (years) | 55.8 ± 9.5 | 54.7 ± 10.4 | 0.246 |
BMI (kg/m2) | 24.3 ± 3.3 | 22.2 ± 2.5 | < 0.001 |
Sex (Male, %) | 250 (71.8) | 102 (64.6) | 0.099 |
HBsAg (%) | 197 (56.6) | 74 (46.8) | 0.041 |
Hepatitis C (%) | 19 (5.5) | 4 (2.5) | 0.143 |
Cirrhosis (%) | 203 (58.3) | 66 (41.8) | 0.001 |
Tumor number (Multiple, %) | 43 (12.4) | 23 (14.6) | 0.496 |
Capsule (Incomplete, %) | 28 (8.0) | 57 (36.1) | < 0.001 |
The largest nodule diameter (cm) | 5.4 ± 3.1 | 6.5 ± 4.6 | 0.007 |
WBC (× 109/L) | 6.04 ± 2.09 | 8.34 ± 4.09 | < 0.001 |
Haemoglobin (g/L) | 140.1 ± 15.9 | 124.7 ± 22.5 | < 0.001 |
Platelet count (× 109/L) | 182.7 ± 74.8 | 202.1 ± 99.8 | 0.03 |
MPV (fL) | 14.5 ± 2.5 | 13.3 ± 2.1 | < 0.001 |
PDW (%) | 15.2 ± 2.3 | 13.2 ± 2.2 | < 0.001 |
AST (U/L) | 29 (22–43) | 41 (26–77) | < 0.001 |
ALT (U/L) | 30 (19–48) | 56 (29–116) | < 0.001 |
γ-GGT (U/L) | 65 (33–138) | 96 (51–196) | < 0.001 |
Total bilirubin (μmol/L) | 14.5 (11.2–18.2) | 20.1 (14.3–37.1) | < 0.001 |
AFP (ng/mL) | 6.08 (2.61–97.4) | 6.23 (2.70–270.1) | 0.818 |
CA19-9 (U/mL) | 22.8 (11.3–50.5) | 23.5 (12.2–59.4) | 0.829 |
FIB-4 | 2.8 (1.7–4.7) | 1.9 (1.1–3.0) | 0.014 |
APRI | 0.7 (0.4–1.4) | 0.7 (0.3–1.2) | < 0.001 |
NLR | 2.87 ± 1.76 | 4.03 ± 1.94 | < 0.001 |